CB1 and CB2 receptor pharmacology

Cannabinoids and the Brain

Volumn , Issue , 2008, Pages 91-99

  Pertwee, Roger G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919964025     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-74349-3_7     Document Type: Chapter

References (34)

1. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A (1994) (R)-methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37:1889-1893.
2. 9- Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271:9902-9905.
3. Cichewicz DL (2004) Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74:1317-1324.
4. 1 vanilloid receptor "hybrid" ligands. Biochem Biophys Res Commun 281:444-451.
5. Fernández-Ruiz J, González S (2005) Cannabinoid control of motor function at the basal ganglia. In: Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology. Heidelberg: Springer-Verlag, Vol. 168, pp. 479-507.
6. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
7. Idris AI, Van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH (2005) Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 11:774-779.
8. Izzo AA, Coutts AA (2005) Cannabinoids and the digestive tract. In: Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology. Heidelberg: Springer-Verlag, Vol. 168, pp. 573-598.
9. Kwiatkowska M, Parker LA, Burton P, Mechoulam R (2004) A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 174:254-259.
10. 1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 312:875-883.
11. 1 cannabinoid receptors. Br J Pharmacol 141:253-262.
12. Leterrier C, Laine J, Darmon M, Boudin H, Rossier J, Lenkei Z (2006) Constitutive activation drives compartment-selective endocytosis and axonal targeting of type 1 cannabinoid receptors. J Neurosci 26:3141-3153.
13. Lu D, Meng Z, Thakur GA, Fan P, Steed J, Tartal CL, Hurst DP, Reggio PH, Deschamps JR, Parrish DA, George C, Järbe TUC, Lamb RJ, Makriyannis A (2005) Adamantyl cannabinoids: A novel class of cannabinergic ligands. J Med Chem 48:4576-4585.
14. Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT, Gonsiorek W, Schwarz MA, Lavey B, Kozlowski JA, Narula SK, Lundell DJ, Hipkin RW, Bober LA (2006) A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 316:780-788.
15. 2, regulates bone mass. Proc Natl Acad Sci USA 103:696-701.
16. 2 receptors. Pharmacol Ther 74:129-180.
17. Pertwee RG (1999) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6:635-664.
18. Pertwee RG (2000) Cannabinoid receptor ligands: clinical and neuropharmacological considerations relevant to future drug discovery and development. Exp Opin Investig Drugs 9:1553-1571.
19. 1 receptors. Life Sci 76:1307-1324.
20. Pertwee RG (2005b) Pharmacological actions of cannabinoids. In: Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology. Heidelberg: Springer-Verlag, Vol. 168, pp. 1-51.
21. Pertwee RG (2005c) The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 7:E625-E654.
22. 2 receptors. In: Reggio P, ed. The Cannabinoid Receptors (in press).
23. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
24. 2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650.
25. Robson P (2005) Human studies of cannabinoids and medicinal cannabis. In: Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacology. Heidelberg: Springer-Verlag, Vol. 168, pp. 719-756.
26. 2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126:665-672.
27. 8-tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol 128:735-743.
28. 1 cannabinoid receptor. J Pharmacol Exp Ther 306:363-370.
29. 1 receptor-dependent G-protein activation in rat cerebellar membranes. Br J Pharmacol 134:664-672.
30. 1 receptors. Br J Pharmacol 140:1451-1459.
31. 2 receptor. Br J Pharmacol 145:636-645.
32. 1 receptor activity. J Biol Chem 282:7753-7757.
33. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT (2005) Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48:658-672.
34. 2 receptor? Br J Pharmacol 149:145-154.